Biocrine drug discovery strategy
Biocrine is dedicated to find a solution for diabetes, a disease that affects millions of people around the globe. The research we aim to commercialize is funneled into four key areas around different aspects of diabetes progression and molecular reactions:
- Enhancement of insulin release only at high blood sugar levels
- Make insulin release by beta-cells more sensitive to glucose: Only high blood sugar levels should result in insulin release. At normal or low levels, insulin should not be released by the beta-cells. Unnecessary high insulin release may result in cancer
- Suppression of glucagon release
- At high blood sugar levels, glucagon release by alpha-cells should be suppressed: The more glucagon, the more glucose is released by liver, leading to even higher blood sugar levels. Too much glucagon represents one of the defects of type 2-diabetes. Adequate regulation of glucagon release is important for glucose content regulation.
- Modification of somatostatin release and its receptor
- Somatostatin serves as a local regulator of hormone release within the endocrine pancreas.
- Preservation of beta cell mass
- Preserve beta cell mass in the endocrine pancreas
The Research programs at Biocrine are the most well-defined and formulated projects from the research center. Each program addresses at least one of the key areas.